Navigation Links
TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity

JACKSONVILLE, Fla., March 16 /PRNewswire/ -- TauTaTis, Inc. announces that its lead compound for inhibition of tau protein pathology, the specific neurodegenerative process in Alzheimer's Disease, has been recognized as the most potent inhibitor of the activity of the Parkinson's Disease gene LRRK2 reported to date. Mutations of this gene are believed to increase its activity, and are the most genetic frequent cause of Parkinson's Disease.

TauTaTis' lead compound is a proprietary small molecule that has shown good tolerability in small animals with chronic oral dosing, and enters the brain at therapeutically relevant concentrations. It is therefore a promising development candidate for two of the most important degenerative neurological conditions of the aged population.

Parkinson's Disease is the second most common progressive neurodegenerative disease after Alzheimer's Disease. About 1 million patients are living with Parkinson's Disease in the US. Symptoms progress from tremor to progressive loss of movement control and rigidity. In some instances the disease may progress further to dementia, sometimes involving the type of neurodegeneration seen in Alzheimer's Disease. Most cases are not obviously linked to genetic mutations, but about 10% of the cases are inherited. Several genes have been identified as drivers of the disease, with LRRK2 being the most prominent.

Current treatments of Parkinson's Disease help to offset symptoms for a limited period of time, but do not alter the prognosis of the disease, which would require to stop the loss of nerve cells, a feat not accomplished in any neurodegenerative disorder to date.

"LRRK2 is one of the most promising targets to fundamentally address a vexing disorder that has not seen any improvements of the therapeutic standard in a long time. This exciting discovery significantly broadens the scope of our lead development program, which targets the biological basis of neurodegenerative disease. It also suggests that there may be underlying commonalities in seemingly disparate disorders. Based on encouraging data for our lead compound in several therapeutic areas the company will seek to access several translational grant mechanisms for further development. If successful, funds of up to $2.5 million could become available from such sources by summer or fall of 2009," comments Dr. Hanno Roder, Founder, Chairman and CEO of TauTaTis, Inc.

TauTaTis, Inc. ( is an early stage company centered on the preclinical and clinical development of compounds, which directly interfere with aberrant biochemical processes in degenerating nerve cells. Its lead compound is the result of an optimization process conducted over more than a decade involving an integrated process of research into disease mechanisms, extensive target profiling, model development and medicinal chemistry.

    Dr. Hanno Roder
    TauTaTis, Inc.
    Tel.:  +1-904-220-1283
    Fax:  +1-904-221-6013


SOURCE TauTaTis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
2. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
3. deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
4. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
5. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
6. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
7. Researchers discover a potential on-off switch for nanoelectronics
8. Research highlights potential for improved solar cells
9. Accidental discovery has potential for new applications in packaging
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider of ... , today announced that the company has set a new quarterly ... quarter on quarter growth posted for Q3 of 2014 to Q3 ... Mexico , with the establishment of an ... --> United Kingdom and ...
(Date:11/24/2015)... ... , ... This fall, global software solutions leader SAP and AdVenture Capital brought ... pitch their BIG ideas to improve health and wellness in their schools. , Now, ... the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, ...
(Date:11/24/2015)... LEXINGTON, Massachusetts , November 24, 2015 ... Officer, will participate in the Piper Jaffray 27 th Annual ... on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. ... Poulton , Chief Financial Officer, will participate in the Piper Jaffray ... City , NY on Tuesday, December 1, 2015, at 8:30 ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... 2015  The J. Craig Venter Institute (JCVI) policy ... and Biosecurity: Lessons Learned and Options for the Future," ... Human Services guidance for synthetic biology providers has worked ... --> --> Synthetic biology promises ... to pose unique biosecurity threats. It now is easier ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):